Allogeneic marrow transplantation for acute leukemia in relapse

Leuk Res. 1982;6(3):383-7. doi: 10.1016/0145-2126(82)90101-1.

Abstract

The results of allogeneic marrow transplantation in 75 patients with acute lymphoblastic leukemia and 63 patients with acute non-lymphoblastic leukemia in relapse are reviewed. The effects of various chemotherapeutic regimens added to the basic regimen of cyclophosphamide (Cy) 60 mg/kg given on each of two successive days followed by 1000 rad of total body irradiation (TBI) were evaluated. The regimens tested were dimethylbusulphan (DMB), 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) and daunorubicin. Seventeen of 138 patients are alive between three and nine and a half years from transplantation. The addition of other chemotherapeutic agents to th basic Cy and TBI regimen did not decrease relapse frequency or prolong survival.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Follow-Up Studies
  • Humans
  • Infant
  • Leukemia / drug therapy
  • Leukemia / radiotherapy
  • Leukemia / therapy*
  • Leukemia, Lymphoid / therapy
  • Middle Aged
  • Recurrence
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide